- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| ONO PHARMACEUTICAL CO LTD ADR Aktie jetzt für 0€ handeln | |||||
| 01.08. | Ono Pharmaceutical reports FQ1 results | 1 | Seeking Alpha | ||
| 01.08. | Ono Pharmaceutical Co. Ltd. Reports Retreat In Q1 Bottom Line | 309 | AFX News | WASHINGTON (dpa-AFX) - Ono Pharmaceutical Co. Ltd. (OPHLF.PK) revealed earnings for first quarter that Drops, from the same period last yearThe company's earnings totaled JPY17.673 billion,... ► Artikel lesen | |
| 23.06. | Vertex and Ono Pharmaceutical form exclusive alliance for Povetacicept in Japan and South Korea | 18 | Seeking Alpha | ||
| 11.06. | LigaChem Biosciences Secures 3rd Milestone Payment from Ono Pharmaceutical | 5 | BusinessKorea | ||
| 28.05. | Merck KGaA shares phase 3 rare tumor data ahead of showdown with Daiichi and Ono | 28 | FierceBiotech | ||
| 08.05. | Ono Pharmaceutical reports FY results | 15 | Seeking Alpha | ||
| 29.04. | Ono Pharma lays off 83 staffers at Cambridge site | 7 | FierceBiotech | ||
| 12.03. | Ono earmarks $940m to gain rare blood cancer therapy from Ionis | 8 | Pharmaceutical Technology | ||
| 12.03. | Ono pays $280M to license Ionis rare disease drug | 4 | BioPharma Dive | ||
| 12.03. | Ionis Pharmaceuticals Partners With Japan-Based Ono Pharmaceutical For Rare Blood Disease Drug In Over $800 Million Deal | 2 | Benzinga.com | ||
| 12.03. | Ionis Out-Licenses Rights for Rare Blood Cancer Drug to Ono | 6 | Zacks | ||
| 12.03. | Ono pays $280M upfront for Ionis' antisense oligonucleotide for rare blood cancer | 4 | FierceBiotech | ||
| 04.03. | DelveInsight Business Research, LLP: Ono's ROMVIMZA Approval Shakes Up Tenosynovial Giant Cell Tumors Market, Challenging Daiichi Sankyo's TURALIO Dominance | DelveInsight | 902 | PR Newswire | On February 14, 2025, Ono Pharmaceuticals secured FDA approval for vimseltinib, a therapy for tenosynovial giant cell tumor (TGCT), which will be marketed as ROMVIMZA. This approval places... ► Artikel lesen | |
| 04.03. | DelveInsight Business Research, LLP: Ono's ROMVIMZA Approval Shakes Up Tenosynovial Giant Cell Tumors Market, Challenging Daiichi Sankyo's TURALIO Dominance | DelveInsight | 988 | PR Newswire | On February 14, 2025, Ono Pharmaceuticals secured FDA approval for vimseltinib, a therapy for tenosynovial giant cell tumor (TGCT), which will be marketed as ROMVIMZA. This approval places... ► Artikel lesen | |
| 18.02. | Ono Pharma Drug Acquired in $2.4B Deal Wins FDA Approval for Treating Rare Type of Tumor | 8 | MedCity News | ||
| 09.11.24 | Fate Therapeutics, Inc.: Fate Therapeutics Highlights Cancer-selective, HER2-Targeting Profile of FT825 / ONO-8250 CAR T-cell Product Candidate for Treatment of Advanced Solid Tumors at 2024 SITC Annual ... | 423 | GlobeNewswire (Europe) | Novel H2CasMab-2 Antigen Binding Domain Shown to Preferentially Target HER2 Expressed on Tumor Cells in Preclinical Studies Initial Low-Dose Cohort of FT825 / ONO-8250 as Monotherapy Shows Favorable... ► Artikel lesen | |
| 07.10.24 | Kinaxis Inc.: Kinaxis unterstützt das Lieferkettenmanagement von Ono Pharmaceutical | 583 | Business Wire | Kinaxis stellt Plattform für die End-to-End-Lieferkettenorchestrierung zur Unterstützung des weiteren globalen Wachstums von Ono Pharmaceutical bereit Kinaxis Inc. (TSX:KXS), ein Weltmarktführer... ► Artikel lesen | |
| 12.09.24 | Turbine Achieves Key Milestone in Collaboration with Ono Pharmaceutical | 532 | Business Wire | - Turbine has successfully completed the first phase of its oncology target identification and validation collaboration with Ono - Ono's selection of multiple targets identified using Turbine's... ► Artikel lesen |
18 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| GILEAD SCIENCES | 101,22 | +0,08 % | Telegram Trader AWSX: Gilead Sciences nach Kurssprung: Auf diese Marken kommt es jetzt an! | ||
| CANOPY GROWTH | 1,124 | +0,72 % | Märkte am Morgen: Bitcoin, Thyssen, Cancom, Glencore, Expedia, Under Armour, Canopy, BYD/Tesla | Der DAX hat sich am Freitag mit leichten Verlusten ins Wochenende verabschiedet. Trotzdem hat der deutsche Leitindex eine starke Woche hinter sich. Unter dem Strich ging es fast 3,2 Prozent nach oben.Auch... ► Artikel lesen | |
| MERCK & CO | 72,10 | +0,14 % | Health Canada Approves Merck's Keytruda For Patients With Resectable Locally Advanced HNSCC | KENILWORTH (NJ) (dpa-AFX) - Merck & Co Inc. (MRK) on Wednesday said Health Canada has approved Keytruda for the treatment of adult patients with resectable locally advanced head and neck squamous... ► Artikel lesen | |
| HALO COLLECTIVE | 0,010 | 0,00 % | Waters Corporation Buys Halo Labs | WASHINGTON (dpa-AFX) - Waters Corporation (WAT), an analytical instruments and software firm, said on Wednesday that it has acquired Halo Labs, a company focused on specialized imaging technologies... ► Artikel lesen | |
| JAGUAR HEALTH | 2,095 | +1,21 % | Jaguar Health, Inc.: Jaguar Health Reports Second Quarter 2025 Financials: Net Q2 2025 Revenue Up Approximately 35% Versus Net Q1 2025 Revenue | The combined net Q2 2025 revenue of approximately $3.0 million for prescription and non-prescription products, including license revenue, increased approximately 35% versus net Q1 2025 revenue of approximately... ► Artikel lesen | |
| MADRIGAL PHARMACEUTICALS | 312,10 | -1,20 % | Piper Sandler reiterates Overweight rating on Madrigal stock amid strong launch | ||
| IQVIA | 163,10 | -0,15 % | Kexing Biopharm Enters Strategic Partnership with IQVIA to Accelerate Global Expansion | SHENZHEN, China, Aug. 11, 2025 /PRNewswire/ -- Kexing Biopharm (688136.SH) has officially entered into a comprehensive strategic partnership with IQVIA(NYSE:IQV), a global leader in clinical... ► Artikel lesen | |
| AZENTA | 26,600 | +2,31 % | Azenta Reports Third Quarter Results for Fiscal 2025, Ended June 30, 2025; Reiterates Full Year Fiscal 2025 Guidance | BURLINGTON, Mass., Aug. 5, 2025 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) today reported financial results for the third quarter ended June 30, 2025.
... ► Artikel lesen | |
| PROTHENA | 6,900 | -2,82 % | Prothena Corporation plc: Prothena Announces that Novo Nordisk Will Advance Coramitug (Formerly PRX004) into Phase 3 Development for ATTR Amyloidosis with Cardiomyopathy | Coramitug is a potential first-in-class amyloid depleter antibody for the treatment of ATTR amyloidosis with cardiomyopathy1-3
Novo Nordisk successfully completed a Phase 2 trial with coramitug... ► Artikel lesen | |
| ALMIRALL | 11,140 | +0,18 % | Absci Corporation: Almirall and Absci Expand AI Drug Creation Collaboration Adding a Second Dermatology Target | Almirall selects second target in AI Drug Creation collaborationExpanded collaboration builds on Absci's successful de novo molecule design for difficult-to-drug targets in the first stage of the... ► Artikel lesen | |
| FUJI PHARMA | 8,350 | +0,60 % | Dividendenbekanntmachungen (28.03.2025) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) ABERDEEN GROUP PLC ADR US00108N1000 0,3716 USD 0,3442 EUR ACOM CO LTD JP3108600002 7 JPY 0,0429 EUR ADVANEX INC JP3213400009 20... ► Artikel lesen | |
| FINANCIERE DE TUBIZE | 157,40 | -0,13 % | Financière de Tubize SA: Financière de Tubize - 2025 half-year financial report | Half-year financial report 2025Regulated information 2 August 2025
The board of directors of Financière de Tubize has established the 2025 half-year report. This report is available on the website... ► Artikel lesen | |
| BAYER | 27,045 | +1,56 % | Bayer-Aktie: Kurs mit wenig Bewegung (25,77 €) | Am deutschen Aktienmarkt ist der Anteilsschein von Bayer zur Stunde unauffällig. Die Aktie notiert gegenwärtig bei 25,77 Euro. Ein minimales Kursplus von 0,21 Prozent zeigt die Kurstafel für das Wertpapier... ► Artikel lesen | |
| NOVO NORDISK | 44,100 | +0,10 % | Novo Nordisk und Eli Lilly: Wachstumsstory oder gefährliche Blase? | Novo Nordisk erlebt einen dramatischen Kursverfall, während Eli Lilly trotz starker Zahlen unter Druck steht. Anleger stehen vor schwierigen Fragen Den vollständigen Artikel lesen ... ► Artikel lesen | |
| MERCK KGAA | 112,05 | +0,99 % | UBS stuft MERCK KGAA auf 'Buy' | ZÜRICH (dpa-AFX Analyser) - Die Schweizer Großbank UBS hat das Kursziel für Merck KGaA nach Quartalszahlen von 162 auf 154 Euro gesenkt, die Einstufung aber auf "Buy" belassen. Diese seien unsauber... ► Artikel lesen |
Das Unternehmen ONO PHARMACEUTICAL CO LTD ADR kann der Branche Pharma zugeordnet werden. Die relative Kursveränderung beträgt aktuell 0,00 % bei einem Aktienkurs von 3,220 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ONO PHARMACEUTICAL CO LTD ADR finden Sie auf Wallstreet Online.